Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?

Mike Drummond ()
Additional contact information
Mike Drummond: Centre for Health Economics, The University of York

No 088chedp, Working Papers from Centre for Health Economics, University of York

Abstract: In the summer of 1990, the Australian government took a major step by requiring evidence of cost-effectiveness of new medicines prior to reimbursement by the public health care system. This paper assesses whether the methodological principles behind the guidelines are sound and whether they raise important new logistical and policy implications. It is concluded that, whilst the guidelines may represent ‘the thin end of the wedge’ for the pharmaceutical industry, in that other countries may follow the Australian lead, they also may represent the ‘thin end of the boomerang’ for government. Namely, the development of explicit guidelines for public funding decisions concerning new health technologies, places as many demands on funders (the government) as it does on the suppliers (the industry).

Keywords: pharmaceutical industry; Australia; medicines (search for similar items in EconPapers)
Pages: 24 pages
Date: 1991-09
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.york.ac.uk/media/che/documents/papers/d ... ion%20Paper%2088.pdf First version, 1991 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:chy:respap:88chedp

Access Statistics for this paper

More papers in Working Papers from Centre for Health Economics, University of York Contact information at EDIRC.
Bibliographic data for series maintained by Gill Forder ().